All Episodes
OIS Podcast | Ophthalmology's leading Podcast — 426 episodes
Corneal Health Innovations and Therapeutics
How Interventional Glaucoma is Advancing Eye Care
Tackling New Territory and Forming Partnerships
Malvina Eydelman and the Bright Future of Innovation for Ophthalmology
Adrienne Graves, Ph.D. on the Future Direction of Ophthalmic Innovation
A Unique Approach to Tackling the Obstacles of Ophthalmology
Creating an Easier-to-Navigate World for Children
Rolling Up Sleeves with David Esposito and Connie Chang
The OIS Situation Room: Navigating healthcare in a shifting world order
Unlocking Breakthroughs in Ocular Surface Treatment
Pharma, Devices & More: Inside the Future of Glaukos
Discover the Future of Non-Invasive Glaucoma Care
Transforming Myopia Treatment: Perry Sternberg Talks SYD-101
Unlocking the Uveoscleral Pathway: Adam Szaronos on Bio-Interventional Innovation in Glaucoma
Bringing Presbyopia Back to the Forefront: Paul Smith of Orasis on The Rob & Jai Show, an Edition of the OIS Podcast
The View from the Street: Industry Trends, Strategic Shifts & Navigating Uncertainty
Breaking Barriers in Sustained Drug Delivery: Michael O’Rourke on The Rob & Jai Show edition of the OIS Podcast
Industry Titans Talk Ophthalmic Innovation: Andrew Stewart & Anthony Wallace on the Rob & Jai Show
A Visionary Approach to Uveitis: Tarsier Pharma’s Disruptive Innovation
Next-Gen Innovators: Dr. Vikram Shankar on Advancing Patient Safety and Sustainability with Dropmate
Insights from a Leader: Dave LeCause on Commercial Strategy and Innovation in Eye Care
The Power of Collaboration: From Early-Stage Innovation to Commercial Strategy
Redefining Ophthalmic Innovation: Stuart Therapeutics’ Journey Beyond Dry Eye
Company Quick Takes
Transforming Corneal Care
Revolutionizing Eye Surgery
The Future of Vision Technology
Revolutionizing Corneal Health
Venture Insights On Retinal Innovation
The View from the Street
Celebrating 400 Episodes of OIS
Advances in Corneal Health
Revolutionizing Eye Care
Todays Therapies are Not Sufficient: A Marketplace Ripe for Innovation
AI and Robotics Transforming Retina Medicine
Exploring the FDA
Empathy in Action
From Ophthalmology Clinics to Business Leadership
Exploring the Future of Eye Care
5 Mistakes to Avoid in Biotech Investor Pitch Decks
Unlocking the Future of Presbyopia Treatment
Revolutionizing Ophthalmic Care
Insights from Startup Leaders on Commercial Strategy and Funding
Maximizing the Value of Your Board of Directors
Quick Takes From Ophthalmology Start-Ups
Revolutionizing Retina Care Beyond Injections
Revolutionizing Glaucoma Treatment and Innovation Insights
Ophthea's Transformative Shift, Clinical Successes, and Visionary Innovation
Building an Enterprise Under the Radar
Approachable Regenerative Medicine
The Bausch + Lomb Buzz, with Andrew Stewart and Yehia Hashad, MD
C-Suite Quick Takes: OIS Goes Behind the Scenes with Four Emerging Biotech Companies
CEO Quick Takes
The Latest on At-Home OCT
Accessing Charitable Resources
What’s New in Ocular Surface Disease?
Accessing Capital and Navigating M&As
When Is the Right Time to Form a Spin-Out? With Wesley Jackson, PhD, Valitor
Commercializing Demedex Blepharitis
From Lab Learning to Machine Learning, with Daniela Ferrara, Genentech
How Digital Innovation is Advancing Ophthalmology
Fueling the Innovation Engine, With Christoph Vonwiller, Johnson & Johnson Vision
Credibility, Cash, and Capability: The Benefits of Strategic Partnership, with Brian Culley, Lineage Cell Therapeutics
A Fast, Fun Future, with Warren Foust and Magda Michna, PhD, Staar Surgical
How Retina Physicians Can Use AI, With Natasa Jovic, RetinAI
The Inspiration Behind Syfovre, with Cedric Francois
Taking the Road Less Traveled, With Jod Mehta, Singapore National Eye Center
The 3 Ingredients of a Successful Dry Eye Product, With Barry Linder, MD, Eyedetec Medical
Meeting the Needs of Ophthalmic Surgeons, with Ed Timm, Mobius Therapeutics
Pharma’s All or None, with Gianluca Rossetti, Dompé
How Science Drives Decisions at Dompé, with Georgea Pasedis
How Bausch + Lomb Identifies Product Gaps, With Anthony Wallace
Ocular Surface Disease Spotlight
Spotlight on Myopia
Practicing and Advising on Medicine
Multimodal Myopia Management
Changing the Glaucoma Monitoring Paradigm
Metaverse Medicine
Perception, Vision, and Gaming
New Possibilities for Corneal Disease Treatment
Sit-downs with Eight OIS XII All-Stars
Expert Panel: How to Launch a Product
Setting the Standards in Imaging
From Leading Global R&D Teams to Funding Startups
The Potential of Entire-Eye OCT Imaging
Launching a Novel Dry Eye Product
Meeting China’s Unmet Need
The Game Changer
Spotlight on OIS Israel at MIXiii
Rayner’s Tim Clover on KOLs and IOLs
Glenn Tookey’s Mission Against Blindness
Democratizing Cell Therapy
Santen’s Dr. Sallstig on People, Passion, and Performance
Great Minds Think Differently
MedTech Ophthalmology European VC Panel
Flying Eye Hospitals and Machine Mentoring, with Orbis International
Early-Stage Retina Drug Development Financing
OIS Retina 2022: How to Execute New Treatments for Dry AMD and GA
Spotlight On Gene & Cell Therapy
Early-Stage Retina Drug Development Financing
Ashley Brissette, MD: Academic and Eye-Focused Skincare Entrepreneur
Inside the Ocular Biofactory, with Thomas Chalberg, PhD
Creating Synergies Between Portfolio Companies, with Yaacov Michlin, BioLight
Dr. Raj Agrawal’s Dual Missions
Roesky’s Quest: Durable Dry Eye Therapy
Seizing Opportunities with Novartis’ Dr. Jill Hopkins
Surfing Between Academic Medicine and Innovation with William Freeman, MD
Bilal Khan, New World Medical, on Balancing Mission with Profitability
Success From Failure With Iveric Bio’s Dr. Pravin Dugel
Treating ‘Lazy Eye’ with Screen Time
Tresserras’ Knack With Academic Assets
Setting Innovation Guideposts, with Manoj Vyas & Sanjeev Ganatra, CBCC Global Research
From Enterprise CEO to VC Founder, with Richel Liu
Solving the Presbyopia Problem, with Robin Sears
Trying It All and Succeeding, With Adrienne Graves
A Laser-Focused Business Model, with Nir Katchinskiy, PhD and Lahav Gil
The Coast to Coast Journey from Academic Research to Janssen Pharmaceuticals with Daniel Chao, MD, PhD
What’s New in Drug Delivery?
Passionate Pursuits, With Brian Strem, Kiora Pharmaceuticals
Visionary Ventures, with Lori-Ann Christie
Ophthalmology Innovation Year in Review
Treating the Untreatable Using Your Own Patient Experience, with Diana Driscoll, OD
Cracking the U.S. Dry Eye Market, With Brent Jones, CCO, I-MED Pharma
Moving From Medicine to Industry, With David Tanzer and Kerrie Brady
Faster, Better, Smarter, Cheaper, with Bill McPhee
Industry Insights on the Glaucoma Market from OIS Glaucoma Innovation Showcase
DIY Commercialization with Michael Gertner, MD
Change Creates Opportunity with Ramin Valian
Finding and Funding Assets in Retina, from OIS Retina@ASRS
The Next Cycle of Retinal Surgery Innovation, with Stanley Chang, MD
Solving the Dry Eye Mystery, With Jeffrey Krall, Neurolens
Following Intellectual Passions, With Dr. Baruch Kupperman
Revolutionizing Cataract Surgery from Innovation to Commercialization
From Big Pharma Lawyer to Eye Care Disruptor—IACTA Pharmaceuticals Founder & CEO Damon Burrows
Leading a Young Company with a Five-Generation History with Jean-Frédéric Chibret
Intimate Discussions from OIS Israel Innovation Showcase
Leading a Global Leader, with Pierre Billardon
Living the Dream with Donald Korb, OD
Discovering the Therapeutic Power of Collagen Mimetics
Developing a Clear Vision for a Clinical-Stage Company with Ben Bergo
Building a Best-in-Class Company for a Best-in-Class Therapy: LENZ Therapeutics CEO Eef Schimmelpennink
Balancing a Passion for Science & Business — Alcon’s Jeannette Bankes
The 3 T’s - Technique, Technology and Teaching with Steve Charles, MD
Paul Ryb, the Ability to Live & Succeed with Sight Loss
The Architect of Pharmaceuticals with Marc Gleeson, CEO of Azura Ophthalmics
Vision is Everything with Samsara’s Tom Ruggia
Zeiss Meditec’s Euan Thomson Says Data at Scale Will Enable New Insights in Healthcare
Roll Up Your Sleeves with Oyster Point’s John Snisarenko
B+L’s Chuck Hess is Looking to Change the Game in Ophthalmology
From Competitive Athlete To Pharma CEO
Fueled by Passion to Advance Development
Taking Alcon Back to Basics
Earning the Right to Ask for the Business with Nick Curtis of LENSAR
Drug Hunter by Day with Arthur Suckow, PhD
Dr. Bala Ambati Discusses The Long Journey from Idea to Impact
Building Value for Pipeline Assets with Mina Sooch
Paul Karpecki, OD, FAAO, Leads a Panel of Industry Experts in a Discussion on the Dry Eye Landscape
Ashley Brissette, MD Leads Discussion with KOLs on the Complexities and Management of Dry Eye Disease
Building Trust in Business
The Reversal of Age-Related Ophthalmic Disorders
KOLs Speak Out on the Future of Gene Therapy
The Sky’s the Limit with the Venerable Vince Anido
Dr. Cal Roberts’ Latest Leap to Lighthouse
The Vision of TearClear’s Future with CEO, Robert Dempsey
Navigating Regulatory Hurdles with Kim Brazzell, PhD
Banishing Bureaucracy at BVI
Invest in 2021 with the Best in Ophthalmic Business
Venturing into Ophthalmology with ExSight
Outlook’s Plan for Bevacizumab-vikg
A Vision for Business
OIS Industry Panel on Retina Start-ups
Investing in the Future of Ophthalmology
KOL Perspective on Glaucoma Therapies and Development
Discussion on Drug Delivery Technologies with Some of Pharma’s Best and Brightest Executives
Nature as an Inspiration for Innovation
A lot of Skill and a Little Bit of Luck
The Steve Jobs of Ophthalmology
Doctor to Doctor with President and CEO, Euclid Systems Corporation
An Intimate Look at the Future of Ocular Gene Therapy
A Stimulating Conversation with Patrik De Haes, MD - CEO at Oxurion
Tim Clover, CEO of Rayner Talks About the Company’s Deep History in Ophthalmology, As Well As Their Future Plans For Innovation
Impacting Lives Using Tomorrow's Technology
A Dynamic Career in Retina
Follow Your Passion
The Apprentice
Never Take No For An Answer
Listening to the Needs of the Customer
Treating Challenges as Opportunities
Au Petit Bonheur La Chance
The Lindstrom Method: Say ‘Yes’ to Opportunities
Dr. Ken Mandell’s Passion for Innovation
Paul Hallen’s View of Retina from the Catbird’s Seat
The Time is Nau!
OIS Israel Panel Dives Into Global Industry Insights and Innovation
From West Point to ONL’s C-Suite - David Esposito
John Hovanesian, MD, on Business, Life, Trends, IOL Technology, and More
OIS Retina Podcast: Interview with Serial Inventor Dr. Mark Humayun
Introducing the OIS Retina Podcast!
Bill Link’s Road to Ophthalmology and VC
Innovation Starts at Home (Updated)
Challenging Conventional Thinking with the Laws of Physics
Elad Kedar and Jeff Weinhuff Share the Recipe for Orasis Pharmaceuticals
Leadership - How to Measure & Motivate in a Startup Environment
Bobak Azamian CEO of Tarsus Addresses Unmet Needs in Blepharitis
Robert Dempsey New CEO of TearClear
Industry Insights into Innovation
Innovating Around the Globe
Collaborative Care in Cataracts & Ocular Surface Disease
Innovation Starts at Home
J&J Vision’s Newly Appointed Worldwide President of Surgical, Mr. Warren Foust Meets with OIS Podcast
J&J’s Tom Frinzi Provides Updates on Innovation Efforts & More
Mitro Opens Up About Aerie’s Programs
Novartis’ Patrick Mooney Gives Inside Look on the Impact of Alcon Spin-Out, Bid to Acquire Xiidra
Avedro CEO Reza Zadno Walks Us Through the Recent IPO, Reimbursement Wins, and Future Potential
Oculis CEO Riad Sherif Talks About Novartis, Alcon, and What’s Promising in His Company’s Pipeline
Oyster Point Pharma CEO Jeffrey Nau Highlights Details of the Company’s Recent B Round, Ponders IPO
Novaliq’s Bernhard Günther Reveals Company’s Fateful Start, Promising Future for Dry Eye Treatments
What Impact Will Gene Therapy Deals Have on Patients? Start-Ups? Jay Duker, MD, Can Speak for Both.
Wall Street Analyst David Nierengarten of Wedbush Dissects Recent Gene Therapy Shopping Spree
BONUS EPISODE: Direct from OIS@SECO - Industry Leaders Speaking Out on the Optometric Channel
Co-Chair James Thimons Walks Us Through the Highs and Even Highers of the First OIS@SECO
Former CMO Brian Levy Sits in the CEO Chair to Lead OcuNexus Down a Bold, New Biopharma Path
Ocutrx CEO Michael Freeman Honors a Promise to Develop AR Device That Could Help AMD Patients See
Paul Karpecki Sees ‘a Lot of Opportunity’ to Grow Treatment of Dry Eye and Other Ocular Diseases
Mark Blumenkranz Previews Upcoming Laser-Based Imaging Workshop, Updates on Big Data, Digital Tech
Justin Schweitzer, OD, of Vance Thompson Vision Talks Glaucoma, Dry Eye, and Clear Career Paths
Dry Eye Coach Hauser Shares Insights on New Treatments, Social Media and Working with Industry
Notal Vision CEO Susan Orr Presents a Clear Future for AMD Patients Conducting OCT Scans at Home
Eric Donnenfeld, MD, Handicaps a Crowded Field in the Race to Develop the Next Dry Eye Blockbuster
Chris Wroten, OD, Recalls Indirect Path into Eye Care, Sees Enormous Need for Upcoming OIS@SECO
Silverstein Traces His Path to Ophthalmology, Interest in Local Affairs, and Reliance of LIV
In our 200th Episode, IDx Founder Shares Wisdom from Recent Success with the FDA, Venture Investors
Web Vision Technologies CEO Bob Main Explains Why He’s Looking for The Right Stuff to Aid Astronauts
With Positive Phase II Dry Eye Data in Hand, What’s Next for Aldeyra’s Promising Pipeline?
Can Swiss Start-Up Ophthorobotics Develop a Robotics System to Deliver Intravitreal Injections?
Eyedaptic CEO Jay Cormier Lays Out Start-Up’s Vision for Augmented Reality Visual Restoration Device
Simple Contacts CEO Joel Wishkovsky Says Start-Up’s App Could Upend Vision Care
James Thimons, OD, Discusses Technology’s Positive Impact on Diagnosing and Treating Eye Disease
Glaukos COO Calcaterra Lays out Pipeline Plans Following iStent inject OK, Reacts to CyPass Recall
Louis Pasquale Discusses Eyenovia’s Trial, Other Causes of Glaucoma, and the Promise of Telemedicine
Peter Menziuso, JJV President, North America Vision Care, Lobbying for Protections in the Contact Lens Rule
REGENXBIO CEO Ken Mills Shines Light on Promising Phase I Trials for Wet AMD Gene Therapy RGX-314
Doug Foster, Chief Strategy Officer of Verana Health, Explains Plans to Replicate IRIS Partnership
Did You Miss OIS Retina (or Just Miss Being in Vancouver?) Hear Highlights from the Meeting Floor
Skimming the Ocular Surface with TFOS’ Amy Gallant Sullivan and Purdue Researcher Chi Hwan Lee
Oyster Point Pharma CEO Nau Takes a Deeper Dive into Just-Released PEARL Trial Results
John Berdahl Speaks on the Importance of Mentors and Changing Views on How to Treat Glaucoma
Surgeon/Engineer Steve Charles Has Advice for Aspiring Inventors: Never Stop Learning; Dump Netflix
CEO Sean Ianchulev Shares Eyenovia's Plans to Replace Eye Drops with New Microdosing Technology
OIS Podcast Update on Dry Eye and MGD - What's Up at J&J, Oyster Point and Tear Film Innovations?
OIS Podcast Finds Out What's Next for Nicox and Zeiss in Two Talks with Michele Garufi and Jim Mazzo
OIS Podcast Talks Fund-raising with Avedro's Reza Zadno, Innovation with Allergan's Bill Meury
Dry Eye Coach Hauser Speaks to How New Tech - Including Social Media - Can Bolster a Practice
AcuFocus President Al Waterhouse Explains Company's Decision to Sell Kamra Inlay to Focus on IOLs
SightLife Surgical CEO Monty Montoya Says Start-Up Is Building Out Cornea Market
CEO David Muller Says Allotex Looks to Create Living Contact Lens with Corneal Allograft
AGTC's Washer on What it Means to Join BIO Board
Shire's Dempsey Highlights Global Leader's Early Bet in Optometry, Role in Upcoming OIS Launch
Hear Details on Feb. 28 Dry Eye Dinner at SECO, Interview with J&J's Dry Eye Head, Joe Boorady
New CEO Mattessich Brings in New Skills, Leadership to Help Ocular Therapeutix Reach Potential
Pixium Vision CEO Sees a Day When Wireless PRIMA Implant Could Bring Vision Back to AMD Patients
We Ask Analysts How Will Pharma and Medtech Companies Spend Billions in Repatriated OUS Profits?
Life After the IPO: What Does Apellis Have Planned After Raising $170m from Public Investors?
Drug Pricing Pro Roger Longman of Real Endpoints Says Spark Therapeutics Is Making the Right Moves
Oyster Point Pharma CEO Jeff Nau Taps Experience, Successful Network to Build Dry Eye Start-up
Using AI to Improve Diagnosis of Disease
Part II: OIS Co-chair Emmett Cunningham, Jr. Delivers Annual Overview on the State of Ophthalmology
OIS Co-chair Emmett Cunningham, Jr., MD. Delivers Annual Overview on the State of Ophthalmology
Dry Eye Diaries: Hear Tales and Hopes from Leaders of Shire, Johnson & Johnson, and TearSolutions
CEO Brent Saunders Lays out Allergan’s Plans for Ophthalmology, Restasis, and Innovation
Donnenfeld, MD, Talks Blue Sea PE Deal, OD/MD Collaboration, and Why OCLI Got CheckedUp
OIS Co-Chair Emmett Cunningham Walks through the Upcoming OIS@AAO Agenda, Reveals New Ways to Engage
Aerie CEO Anido Talks War Rooms, FDA, Rhopressa, Roclatan, and Getting Along with the Neighbors
Gemini CEO McLaughlin Explains How the Precision Therapeutics Start-up Will Take Aim at Eye Disease
What’s Next PanOptica? We Ask CEO Chaney
ExSight Capital, Partner Firas Rahhal, MD, Are Building a Successful Record as Impact Investor
Dr. Pravin Dugel Picks Possible Winners in Race to Deliver New Retinal Treatments
Hatteras’ Shaffer Found a Model That Works at Inspire; Now She Uses It When Making Investments
Digital Health Is Dead? Don’t Tell Mark Blumenkranz, the FDA, or the Organizers of an Oct. Workshop
What Was the Most Difficult Part of Successfully Transitioning to CMO? We Ask B&L’s Cal Roberts
Imperial College’s Dr. Cordeiro Explains How DARC May Bring Early Light to Disease, Shorten Trials
Why Did Charles Semba, MD, Switch Specialties and How Did He Find a Home in Ophthalmology?
OIS@ASRS Co-Chairs Give High Marks and Hopes for Innovators Looking at the Back of the Eye
Should You Be at OIS@ASRS on Thursday? Take an Insider Look at the Agenda with Emmett Cunningham
What Does TearScience Deal Mean for J&J? Group Chair Ashley McEvoy Shines Light on Future Plans
Allegro’s Poised to Deliver Positive News at ASRS; Could an IPO Be Next? We Ask Vicken Karageozian
Double Shot: Two Leading Ophthalmologists Discuss the Impact Innovation Is Having on Eye Care
Investor, Executive Shine Light on Private Equity’s Growing Interest and Influence in Ophthalmology
Sun Pharma’s St. Peter Outlines Company’s Ambitious Plan to Build Ophthalmology Pipeline
Alcon's Attias Touts Growing Pipeline Including Progress in Glaucoma and Google Projects
NEA's Behbahani, with New Fund to Invest, Discusses VC's Strong Interest in Ophthalmology
Implandata Co-Founder Outlines Next Step as Company Scores CE Mark for Continuous IOP Monitoring Device
Mynosys CEO Hendrick Lays Out Next Step for Zepto Following Positive FDA, Strong OUS Launch
Donnenfeld Discusses How New Diagnostics, Treatments Impact His Practice and Patients
COO Tom Mitro Discusses Aerie’s Preparation for Rhopressa Launch, Updates OIS@ASCRS on Pipeline
CEO Ludwin Monz Discusses Zeiss’ Important Management Hires, SMILE, and the Future of Diagnostics
Alice Epitropoulos, MD, on How Xiidra, TrueTear, and Other Treatments Impact Practices, Patients
CEO Ram Rao Discusses Juvene, the Rise of Presbyopia, and How LensGen Raised $21 million
In an Insightful Wrap-up, OIS Co-chairs Share the Top Takeaways from another Successful OIS@ASCRS
Can OIS Help Make Myopia Great Again? Co-chair Kliman Discusses Inventive New Panel, Opportunities
Award Winner Korroch Explains How Eye Banks Have Worked to Ensure Supply Exceeds Demand
What’s the Difference between Creativity and Innovation? Blumenkranz Answers That and Much More
OIS Co-Chair Bill Link Walks Us Through OIS@ASCRS May 4 Agenda and Introduces Flying L Partners
Prolific Investigator Thompson Gives His Take on SMILE, Cross-Linking, Oculeve, and Other Innovations
Co-author Thomas Albini, MD, Explains Why Eye Docs Wrote NEJM Paper to Expose Stem Cell Injuries
Nancy Lurker Discusses Bringing Her Commercial Experience, Insights to Drug Delivery Upstart pSivida
We Ask Dick Lindstrom What Practice Consolidation May Mean for Ophthalmology, Innovation (Pt. 2)
Dick Lindstrom Tells us why Minnesota Eye Consultants Partnered With a Private Equity Firm (Pt. 1)
Apellis CEO Delivers Some Hopeful Pipeline News, and Offers a Cautionary Note on Immigration Debate
Eyes Up! NEI Challenges “Solvers” to Create 3D Retina Organoid that Could Aid Research
Abbie Celniker Shares Her View of Pharma, Ophthalmology from High-flying Third Rock Ventures
Can Presbyopia Therapies Deliver an Encore with its Own Vision-Correcting Eye Drops?
Novartis Sees Clear Opportunity in Encore Vision’s Unique Approach to Correcting Presbyopia
Looking Beyond the Tweets: What Trump’s Pharma Pricing Pledge Might Mean for Ophthalmology
Novaliq’s Positive Phase II Dry Eye Results Present Break from Disappointing Clinical Trial Season
EyeGate Pharma Discusses Early Clinical Trials Success, Promising Pipeline, and Partnership Payouts
What Now? What Does Ophthotech’s Disappointing Phase III Results Mean for Wet AMD, VEGF and PDGF?
Can Lighting Strike Twice? SARCode’s Co-Founder Gadek Takes Helm of Promising Dry Eye Start-up
Andrew Chang Discusses His Move to Lead Global Sales of Zeiss Meditec’s Ophthalmic Devices
What Are Tom Frinzi’s Plans after J&J Acquires AMO? Frinzi Talks J&J, Symfony, and Much More
OIS Editorial Roundtable: What Impact Will a Trump Administration Have on Ophthalmology?
Carl Zeiss’s Jim Mazzo Talks About Failing Fast, the Reply All Button and Reaching the Customer
How it All Began. Allergan’s Herbert Shares Details of His Contribution to Ophthalmology’s Origins
David Pyott on Growing Allergan, Defending Against Acquisitions, and How the Next Chapter Will Read
Live (sort of) from Chicago: OIS Podcast Brings You the Voices of OIS@AAO
Introducing Our Newest Tool – the OIS Index
OIS Founder & Co-Chair Emmett Cunningham Jr. Tells Us What to Watch for Next Week in Chicago
Hear How Preceyes Will Help Usher Robotics into Ophthalmic Surgery
Behind the Deal: McEvoy On Where Will AMO Fit into J&J & What the Deal Means for Eye Care
Live (sort of) from Copenhagen: OIS Podcast Hits the High Points of ESCRS and EuRetina
Xiidra Prior to Shire: How SARcode Took on the Odds to Pursue a New Treatment for Dry Eye
A note from OIS Podcast
100th Episode & Counting
CEO John Kilcoyne Reviews ReVision’s Success with the FDA & its Plans to Roll Out Raindrop
Live from the Floor of OIS@ASRS: Co-Chair Bill Link on What Made the Day Work So Well
What Will Carl Zeiss Meditec’s New Ophthalmology Unit Look Like? We Ask Jim Mazzo.
Clearside Biomedical Finds the Public Markets Despite Diminished Interest in Sector
Can Allegro’s Integrin Peptide Therapy Help Usher in Retina 2.0 for Vitreoretinal Indications?
Godspeed Xiidra. Shire’s Robert Dempsey Introduces the Newest FDA-Approved Treatment for Dry Eye.
What Drives Innovators? Pioneer Mark Humayun, MD, PhD, Shares His Story & Vision for Ophthalmology
A Walk Down Wall Street: Two Analysts Tell You What to Expect From the Markets in the Coming Months
Steven Vold, MD, Sees Enormous Potential in Coming Tide of IOLs, Diagnostics & Potential New Drugs
Aldeyra CEO Highlights Clinical Trial Success of Possible Treatments for Conjunctivitis, Uveitis
Ludwin Monz, PhD, Discusses Zeiss, its Legacy & Where it Pursues New Innovation
Bausch & Lomb’s CMO Cal Roberts on How He Uses His MD & Experience to Build the Right Tool Kit for Ophthalmologists
Dempsey on Building the Shire Brand in Ophthalmology
OISPodcast@ASCRS - Meury: Why Allergan Won’t Miss a Beat in Building Ophthalmology Franchise
What the Heck Happened at OIS@ASCRS?
Graybug Vision – Flush with Cash – Is Making Big Moves to Change its Approach to Finding New Treatments for Wet AMD & Other Eye Disease
Sun Ophthalmics Looks to Build a Brand-New Business in the US
Avedro’s Long Wait for FDA Approval is Over
What are Allergan’s Next Steps?
KOL Corner: Can Complement Inhibitors Treat Macular Degeneration?
Frinzi shares a bit of his plans for AMO
Can Apellis Find a Way to Inhibit the Complement System & Treat Intermediate AMD?
Lewis Handicaps MIGS Market and Explains Glaucoma’s Emergence
VisionCare Battling Back against Macular Degeneration
Heier Talks Anti-Angiopoietin Programs, Clinical Trials & Red Sox
KOL Corner: Alcon, Transcend & Glaucoma 360
What Does the Leadership Shuffle Mean for Ophthalmology?
EyeGate Finds New Paths to Dollars, Deal
Muller Explains Departure from Avedro; Opportunity in New Venture
Inotek’s Southwell and McVicar Have Designs on Treating Glaucoma
Emptying the OIS Reporter’s Notebook After OIS@AAO
Where Will `Pfizergan’ Fit in Ophthalmology
A Rundown of a Record-setting OIS
Celniker Gets Eleven Bio Ready For OIS and Conference Season
Muller on the FDA, PIXL and Dairy Farms
Biogen’s High Hopes For Gene Therapy, Ophthalmology
Understanding Market Cycles: When Could Biotech UnBoom?
Implandata's Hands-On Approach To Tracking IOP
Imprimis’ Baum on Disrupting Compound Pharmacies
Makower: Making Medtech Bigger, Stronger, Faster
ClarVista’s Two-Part Strategy To Premium IOLs
CEO Tom Burns Has Even Bigger Plans For Glaukos
Year 1: What OIS Podcasts Were Most Popular? Part Two
Year 1: What OIS Podcasts Were Most Popular?
A Favorite From The OIS Podcast Stack
Clarus Delivers Good News With $500m Fund
Oculeve Open Ups, Just a Little, on OD-01
Hear Bausch & Lomb’s Ophthalmology Play Book
A discussion of Allergan’s legacy and future in Medtech Ophthalmology
Here is How Big Companies Innovate
Hear How Valeant Innovates, Invests and Acquires
Transcend Medical Ready To Make Move In MIGs
Borrmann Gives View Into AMO’s Innovation Cycle
OIS Optical Overview: Haimovich, Lachman Share Insights On OIS, MIGs, IOLs, etc.
Avedro CEO Muller Answers Questions about the FDA’s Questions
Lindstrom Wins Ophthalmology Innovator Award
Mazzo Details Plans For Kamra Inlay’s Introduction To The US Following FDA Approval
Alternative Financing Approaches
PowerVision’s Cheskin discusses the potential of the company’s accommodating IOL, FluidVision
Alphaeon’s Grant Explains Innovative New Model
Co-Chair Link Gives Overview of Upcoming OIS
Alcon’s Attias Offers Insights on Innovation
Holland Delivers Overview of ASCRS, Ophthalmology
Talley Rostov Works to Improve Global Vision
Blumenkranz Shares His Success, Failures And New Opportunities For Ophthalmic Innovators
Alcon’s Plan For WaveTec’s ORA System
CEO Russ Trenary Discusses InnFocus’ Push into the Competitive MIGs Market
Ophthalmology By The Numbers With Jon Norris of SVB
DigiSight Puts Eye Care in Patients’ Hands
Vance Thompson, MD, Speaks to Importance of Patient “Experience” in a successful practice.
A multi-generational look at ophthalmology with Dr. George O. Waring IV
Second Sight Fulfills Dream
Eleven’s Celniker Talks Leadership, Public Markets, and Phase III Dry Eye Trials
Cunningham: 2015 Could Be A Big Year For Ophthalmology
TearScience CEO Willis Explains Dry Eye Disease’s Emergence
Alimera CEO Myers Shares Lessons From Iluvien FDA Approval
Opening The Door For Premium IOLs
Ocular Therapeutix Starting to Sprint
Alcon Head Jeff George Lays Out Vision
How Thoughtful Consolidation Can Benefit Ophthalmology
How Alcon and Google Could Change the Contact Lens
NASA-Backed Entity Enlists Industry To Battle Eye Disorders Caused By Space Travel
Dirk Sauer Oversees Novartis’ Promising And Productive Ophthalmic Pipeline
Gobiquity Goes Big In Mobile Imaging Diagnostics
Anido Guides Aerie’s Push To Be A “Very Big Player” In Glaucoma
Slade Discusses the Opportunities, and Challenges, of New Technology.
Hear How Avedro’s Muller Is Building A Cross-Linking Powerhouse
Ophthalmology Is A “Leading Franchise” At InterWest
Lindstrom: Ophthalmologists Facing Both Opportunity And Pressure
Cunningham: Strong Signs Ahead For Ophthalmology Innovation
Donnenfeld Bullish on Ophthalmic Innovation
Link Says Versant's Eyes Will Be on Ophthalmology
Mazzo Muses on the FDA, Google and Failing Fast